Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Hormone therapy affects plasma measures of factor VII-activating protease in younger postmenopausal women

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The influence of unilateral oophorectomy on the age of menopause

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Primary prevention of cardiovascular disease with hormone replacement therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Acute and long-term estradiol kinetics in smoking postmenopausal women

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Endometrial cancer, types, prognosis, female hormones and antihormones

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. A distinctive epigenetic ageing profile in human granulosa cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effect of dosage of 17ß-estradiol on uterine growth in Turner syndrome - a randomized controlled clinical pilot trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Lipidomic profiles, lipid trajectories and clinical biomarkers in female elite endurance athletes

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Jørn Sidelmann Mathiasen
  • S.O. Skouby
  • F. Vitzthum
  • H. Schwarz
  • J. Jespersen
View graph of relations
Objectives Current reviews indicate that hormone therapy (HT) has a protective role in coronary heart disease (CHD) in younger postmenopausal women, whereas HT contributes to CHD in older women Factor VII-activating protease (FSAP) is a serine protease that accumulates in unstable atherosclerotic plaques. FSAP is presumably involved in plaque stability and rupture. Reduced plasma concentration of FSAP may be associated with the development and expression of atherosclerosis and may thus contribute to precipitation of CHD. Here we address the potential influence of various HT regimens on plasma measures of FSAP in postmenopausal women treated for I year with different HT formulations or no HT. Methods Six groups of postmenopausal women (n = 139) were allocated to five different HT modalities or no HT Samples were collected at baseline and after 12 months of treatment. Prototype assays were used for the determination of FSAP antigen and FSAP activity. Results The FSAP measures were comparable at baseline. No significant changes were observed in the control group after 12 months. HT in general induced a significant increase in FSAP antigen (7.7 mu g/ml at baseline and 8.0 mu g/ml after 12 months, p = 0.05), FSAP activity (1 54 PEU/ml at baseline and 1.68 PEU/ml after 12 months, p <0.001) and FSAP ratio (202 mPEU/mu g at baseline and 210 mPEU/mu g after 12 months, p = 0.01). Conclusions HT increases the plasma measures of FSAP. This increase may contribute to the protective effect on CHD induced by HT in younger postmenopausal women
Original languageEnglish
JournalClimacteric
Volume13
Issue number4
Pages (from-to)340-346
Number of pages7
ISSN1369-7137
DOIs
Publication statusPublished - 2010

ID: 32300449